Health In Tech 尽管第一季度亏损，但获得了 Maxim Group 的强烈买入评级和 2.50 美元的目标价。 Health In Tech, despite a Q1 loss, gets a strong-buy rating and $2.50 target from Maxim Group.

马克西姆集团(Maxim Group)对保健技术公司(HIT)的购买评级很高,目标价格为2.50美元,尽管报告有Q1损失和收益预期缺失。 Health In Tech (HIT) received a strong-buy rating from Maxim Group with a $2.50 target price, despite reporting a Q1 loss and missing earnings expectations. 该公司为医疗保健提供保险技术平台,此前被华尔街Zen降级。 The company, which offers insurance technology platforms for healthcare, was previously downgraded by Wall Street Zen. 最近,HIT开始为每股0.83美元,平均50天为0.66美元。 HIT opened at $0.83 per share recently, with a 50-day average of $0.66.